$RARE News

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Cantor Fitzgerald Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $96

Ultragenyx Pharmaceutical Inc. (RARE) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Is Ultragenyx (RARE) Reaffirming 2026–2027 Guidance Enough To Offset Its Widening Losses?

Wedbush Maintains Neutral on Ultragenyx Pharmaceutical, Lowers Price Target to $26

Guggenheim Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $43

Ultragenyx to Participate at Bank of America’s 2026 Healthcare Conference

Ultragenyx Pharmaceutical Inc. Q1 2026 Earnings Call Summary

Ultragenyx Pharmaceutical Inc. (RARE) Q1 2026 Earnings Call Transcript

Wells Fargo Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $47

Wedbush Maintains Neutral on Ultragenyx Pharmaceutical, Lowers Price Target to $26

Ultragenyx Pharmaceutical Q1 Earnings Call Highlights

Ultragenyx (RARE) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Ultragenyx (RARE) Reports Q1 Loss, Misses Revenue Estimates

Ultragenyx Pharma (NASDAQ:RARE) Dips After Q1 Miss as Pipeline Catalysts Loom

Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update

Ultragenyx Pharmaceutical Q1 2026 Earnings Call Transcript

Will Arcutis Biotherapeutics, Inc. (ARQT) Report Negative Earnings Next Week? What You Should Know

Ultragenyx to Host Conference Call for First Quarter 2026 Financial Results and Corporate Update

Barclays Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $43